Monoclonal Antibody for Neuropathic Pain

Blockade of novel target, Netrin-4 Unc5B signaling.

Advantage and Core Benefit

  • Obtained anti-human netrin-4 antibodies, which cross-reacts with non-human netrin-4.
  • Commonly used topical injection in pain clinic is available.

Background and Technology

The researchers has revealed that neuropathic pain signaling is mediated by Netrin-4 and its receptor Unc5B, and demonstrated that blockade of Netrin-4-Unc5B signals by siRNA or polyclonal antibody intrathecal administration can alleviate the neuropathic pain (Fig. L).

Now, they have identified the epitope of Netrin-4, and obtained monoclonal antibodies which cross react with rodent netrin-4. Topical administration experiment indicated the mAb could make a medicine with novel mechanism for patients with dysesthesia or allodynia after nerve injury.

Data

  • In rat von Frey Filament test model, 3μg anti-netrin-4 mAb injection into dorsal root ganglion 7days after partial sciatic nerve ligation elevated the withdrawal threshold to the contra-lateral level (Fig. R).

Patent, Publications

WO2015/025770, registered in US/EP/JP, Monoclonal antibody patent not published.

https://doi.org/10.1073/pnas.1402095111, https://doi.org/10.1084/jem.20160877

Researcher

Prof. Toshihide YAMASHITA (Osaka Univ. JAPAN)

Expectations

We are seeking a partner who will in-license and develop the technology further by humanization of mAbs. Details can be disclosed under CDA, mAbs for review can be provided under MTA (paid).

Product No. KJ-04225

Inquiry Form

Your Name (*Required)

E-Mail Address (*Required)

Company Name

Message

Following submission of your inquiry

We will contact you shortly to discuss confidentiality, materials transfer, evaluation steps, and licensing opportunities.

<Notice>

Our support is provided free of charge.
The information submitted on this form is for business development use only.

By clicking "Send", you are agreeing to our Privacy Policy.
If you have questions please reach out to info (at) tech-manage.co.jp.

About Bionauts.jp Tech Manage Corp.
Copyright © Tech Manage Corp. All Rights Reserved.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.